Antimicrobial susceptibility of Acinetobacter clinical isolates among ICU Patients in Sana'a City, Yemen
DOI:
https://doi.org/10.65693/masj.2022.v1i1.14Keywords:
Acinetobacter, Antibiotic resistance, Carbapenems, ICUAbstract
Drug resistant Acinetobacter strains are important causes of nosocomial infections that are difficult to control and treat. This study aimed to determine the antimicrobial susceptibility patterns of Acinetobacter strains obtained from ICU patients belonging to different age groups at hospitalized patients in Sana'a, Yemen. 88 Acinetobacter isolated were collected from the infected patients admitted to the ICU at a private hospital in Sana’a, Yemen, over one year from March 2020 to April 2021. The records were taken from the microbiology department for hospitalized patients. The results showed that out of 88 samples, 87 (98.8%) were Polymyxin B sensitive isolates and only one sample (1.2%) was resistant. Also, the Colistin sensitive isolates were observed in 100% of culture samples. This study found that 94.3% of culture samples were amoxicillin resistant and 90.9% were ampicillin\sulbactam resistant. In addition, Acinetobacter spp. resistance for imipenem, moxifloxacin, meropenem, cefepime, ceftazidime, and ceftriaxone was 95.5, 96.6, 95.5, 97.7, 97.7, and 97.7 %; respectively. The study also revealed the alarming trends of resistance of Acinetobacter strains for the various classes of antimicrobials. It was concluded that improvement of microbiological techniques for earlier and more accurate identification of bacteria is necessary for the selection of appropriate treatments. More careful monitoring for use of broad-spectrum antibiotics should be instituted.
References
1. ECDC, EMEA, The bacterial challenge: time to react, ECDC/EMEA joint technical report, European Centre for Disease Prevention and Control, Stockholm;2009.
2. Lockhart SR, Abramson MA, Beekmann SE, et al. Antimicrobial resistance among gram negative bacilli as causes of infections in intensive care unit patients in the United States between 1993 and 2004, J Clin Microbiol, 2007; vol. 45 p. 3352-3359.
3. Ziglam H., Elahmer O., Amri S., et al. Antimicrobial resistance patterns among Acinetobacter baumannii isolated from burn intensive care unit in Tripoli, Libya. International Arabic Journal of Antimicrobial Agents. 2012;2(3) doi: 10.3823/716.
4. Sohail M, Rashid A, Aslam B, Waseem M, Shahid M, Akram M, Khurshid M, Rasool MH. Antimicrobial susceptibility of Acinetobacter clinical isolates and emerging antibiogram trends for nosocomial infection management. Rev Soc Bras Med Trop. 2016 May-Jun;49(3):300-4. doi: 10.1590/0037-8682-0111-2016. PMID: 27384826.
5. Uwingabiye J, Frikh M, Lemnouer A, Bssaibis F, Belefquih B, Maleb A, Dahraoui S, Belyamani L, Bait A, Haimeur C, Louzi L, Ibrahimi A, Elouennass M. Acinetobacter infections prevalence and frequency of the antibiotics resistance: comparative study of intensive care units versus other hospital units. Pan Afr Med J. 2016 Apr 15; 23:191.
6. Dhingra S, Rahman NAA, Peile E, Rahman M, Sartelli M, Hassali MA, Islam T, Islam S and Haque M (2020). Microbial Resistance Movements: An Overview of Global Public Health Threats Posed by Antimicrobial Resistance, and How Best to Counter. Front. Public Health 8: 535668.doi: 10.3389/fpubh.2020;535668.
7. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect 2006; 12:315-321.
8. Souli M, Kontopidou FV, Koratzanis E, Antoniadou A, Giannitsioti E, Evangelopoulou P, et al. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals. Antimicrob Agents Chemother 2006; 50:3166-3169.
9. M. Dizbay, A. Altuncekic, B. Sezer, K. Ozdemir and D. Arman. Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia. Int J Antimicrob Agents. 2008. 32: 29-32.
10. M. G. Savov E, Borisova M. Multidrug resistant Acinetobacter baumannii: a major concern in the hospital setting. Trakia Journal of Sciences. 2008. 6.
11. D. Wareham, D. Bean, P. Khanna, et al. Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis. 2008. 27: 607-612.).
12. L. Dent, D. Marshall, S. Pratap and R. Hulette. Multidrug resistant Acinetobacter baumannii: a descriptive study in a city hospital. BMC Infect Dis. 2010; 10: 196.
13. Peleg, C. Franklin, J. Bell and D. Spelman. Emergence of carbapenem resistance in Acinetobacter baumannii recovered from blood cultures in Australia. Infect Control Hosp Epidemiol. 2006; 27: 759-761.
14. J. Ye, C. Huang, S. Shie, et al. Multidrug resistant Acinetobacter baumannii: risk factors for appearance of imipenem resistant strains on patients formerly with susceptible strains. PLoS One. 201; 5: e9947.
15. Salgado CD, O’Grady N, Farr BM: Prevention and control of antimicrobial-resistant infections in intensive care patients. Crit Care Med 2005; 33:2373-2382].
16. Brusselaers N, Vogelaers D, Blot S. The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care. 2011 Nov 23;1:4
Downloads
Published
Data Availability Statement
yes
Issue
Section
License
Copyright (c) 2022 د. علي عبدالله اليحوي، د. منير مصلح محمد الوصابي، أ.د. علي الكاف (المؤلف)
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal which means that all content is freely available without charge to the user or their institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, provided the original work is properly cited. All articles are licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
